Aurobindo Pharma Ltd - Company Profile
Powered by 
All the sales intelligence you need on Aurobindo Pharma Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Aurobindo Pharma Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Aurobindo Pharma Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Aurobindo Pharma Ltd (Aurobindo) is a vertically integrated pharmaceutical company. Its primary activities include the development, manufacturing, and commercialization of pharmaceutical products. The company’s product portfolio includes injectables, API, and complex offerings, including biosimilars, vaccines, peptides, and metered dose inhalers. The company's products are used in various therapeutic segments such as neurosciences, cardiovascular, anti-retroviral, anti-diabetics, gastroenterology, and antibiotics. Aurobindo Pharma serves a global customer base, including multinational companies, and caters to their formulation manufacturing needs. The company operates through a network of alliances and partnerships across the globe. It operates manufacturing facilities in India, Brazil, Portugal, and the US; and R&D facilities in India and the US. Aurobindo is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Telangana, 500032
Website
www.aurobindo.com
Telephone
91 40 23736370
No of Employees
29,209
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AUROPHARMA (NSE)
Revenue (2025)
$3.9B
6.1%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
0.5%
(2025 vs 2024)
Market Cap*
$10.0B
Net Profit Margin (2025)
XYZ
-5.3%
(2025 vs 2024)
* As of and is in US$
Aurobindo Pharma Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Formulations: | API Development |
| Antibacterials | Custom Synthesis |
| Central Nervous System | Contract Services |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In July, CuraTeQ Biologics Private Limited received approval from ANVISA (Agencia Nacional de Vigilancia Sanitaria), the National Health Surveillance Agency of Brazil, for its biosimilars manufacturing facility in Hyderabad, Telangana, India. |
| 2026 | Corporate Changes/Expansions | In June, the company opened its new TheraNym Biologics contract manufacturing facility in Hyderabad, Telangana, India. |
| 2026 | Contracts/Agreements | In March, the company signed a captive solar power purchase agreement to acquire upto 26% stake in Swarnaakshu Solar Power Private Limited. |
Competitor Comparison
| Key Parameters | Aurobindo Pharma Ltd | Viatris Inc | Sun Pharmaceutical Industries Ltd | Cipla Ltd | Lupin Ltd |
|---|---|---|---|---|---|
| Headquarters | India | United States of America | India | India | India |
| City | Hyderabad | Canonsburg | Mumbai | Mumbai | Mumbai |
| State/Province | Telangana | Pennsylvania | Maharashtra | Maharashtra | Maharashtra |
| No. of Employees | 29,209 | 30,000 | 47,000 | 31,369 | 26,021 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mangalam Ramasubramanian Kumar | Chairman | Executive Board | 2024 | - |
| Santhanam Subramanian | Chief Financial Officer | Senior Management | 2013 | - |
| N. Ravikiran | Chief Business Officer | Senior Management | 2024 | - |
| Kambam Nityananda Reddy | Vice Chairman; Managing Director | Executive Board | 2022 | - |
| Parveen Kumar Luthra | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer